Top

Strahlentherapie und Onkologie

Published in:

01-08-2017 | Literatur kommentiert

30-Tage-Letalität nach systemischer Chemotherapie

Beobachtungsstudie bei Mamma- und Bronchialkarzinomen

Authors: Dr. Isabella Gruber, Prof. Dr. Gerhard G. Grabenbauer

Published in: Strahlentherapie und Onkologie | Issue 8/2017

Auszug

Welcher Krebspatient profitiert von einer systemischen Chemotherapie – sei es palliativ oder kurativ? Gibt es Patientengruppen mit hoher 30-Tage-Letalität (L30), denen besondere Aufmerksamkeit im klinischen Alltag zuteilwerden muss? Kann die Letalität sogar krankenhausspezifisch sein? Um diese Fragen zu beantworten, suchte die vorliegende Studie nach patienten- und krankenhausspezifischen Faktoren, welche die Frage bei Patienten mit Mammakarzinom und Bronchialkarzinom (NSCLC) nach systemischer Chemotherapie beeinflussen. …

Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, Rashbass J, Chao D, Dewar J, Talbot D, Peake M, Perren T, Wilson C, Dodwell D (2016) 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol 17(9):1203–1216. doi:10.1016/S1470-2045(16)30383-7 CrossRefPubMedPubMedCentral

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH, American Society of Clinical Oncology (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30(13):1553–1561. doi:10.1200/jco.2011.39.9436 CrossRefPubMed

Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A, International Breast Cancer Study Group (2005) Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366(9491):1108–1110CrossRefPubMed

Radford JA, Ryder WD, Dodwell D, Anderson H, Thatcher N (1992) Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer 29A(1):81–86PubMed

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7(9):719–727 (Erratum in: Lancet Oncol (2006) 7(10):797)CrossRefPubMed

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative Group. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350(4):351–360CrossRefPubMed

Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgensztern D et al (2015) Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol 33:870–876CrossRefPubMedPubMedCentral

Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, Rashbass J, Chao D, Dewar J, Talbot D, Peake M, Perren T, Wilson C, Dodwell D (2016) Trust-level 30-day mortality after systemic anticancer treatment for breast and lung cancer in England. Companion report. (August)

Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK (2015) Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol 1(6):778–784. doi:10.1001/jamaoncol.2015.2378 CrossRefPubMedPubMedCentral

10.

Spencer K, Morris E, Dugdale E, Newsham A, Sebag-Montefiore D, Turner R, Hall G, Crellin A (2015) 30 day mortality in adult palliative radiotherapy – a retrospective population based study of 14,972 treatment episodes. Radiother Oncol 115(2):264–271. doi:10.1016/j.radonc.2015.03.023 CrossRefPubMedPubMedCentral

11.

Angelo K, Norum J, Dalhaug A, Pawinski A, Aandahl G, Haukland E, Engljähringer K, Nieder C (2014) Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. Anticancer Res 34(2):877–885PubMed

Title: 30-Tage-Letalität nach systemischer Chemotherapie
Beobachtungsstudie bei Mamma- und Bronchialkarzinomen
Authors: Dr. Isabella Gruber
Prof. Dr. Gerhard G. Grabenbauer
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 8/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-017-1170-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

30-Tage-Letalität nach systemischer Chemotherapie

Beobachtungsstudie bei Mamma- und Bronchialkarzinomen

Auszug

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Auszug

Please log in to get access to this content

Other articles of this Issue 8/2017

Bestrahlung mit zusätzlicher Antiandrogentherapie beim Prostatakarzinomrezidiv

Improved oncologic outcome with chemoradiotherapy followed by surgery in unresectable intrahepatic cholangiocarcinoma

Personalized radiotherapy for invasive breast cancer in 2017

Erratum to: Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters

External-beam radiation therapy combined with limb-sparing surgery in elderly patients (>70 years) with primary soft tissue sarcomas of the extremities

Effects of definitive and salvage radiotherapy on the distribution of lymphocyte subpopulations in prostate cancer patients